 |
|
|
|
|
Looking for qualified candidate? Try our free six month job posting trial
Indiana Life Science Industry Directory
Target your advertising by state, region or nationwide for the same low rate
Banner Advertising | Event Advertising
Endocyte, Inc.
| | | | | Phone: | (765) 463-7175 | | Fax: | (765) 463-9271 | | Year Established: | 1996 | | Ticker: | NVS | | Exchange: | NYSE | | Main Contact: | Matthew Call, VP, Business Development | | | | Other Contacts: | Alison A. Armour, M.B., Ch.B., B.Sc., M.Sc., M.D., MRCP., FRCR, CMO
Iontcho Vlahov Ph.D, VP, Discovery Chemistry
Christopher Leamon, Ph.D., VP, R&D
Philip Low, Ph.D., CSO
Michael T. Andriole, CFO
Mike Sherman, President & CEO
| | | | Company Description | | Endocyte, a Novartis company, is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. | |
|
|
|
|
|
|
|
